

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 19350

Title: Current status and future perspective of companion diagnostics for targeted therapy in gastric cancer

Reviewer's code: 02688242

Reviewer's country: Japan

Science editor: Ya-Juan Ma

Date sent for review: 2015-05-11 08:59

Date reviewed: 2015-05-18 15:09

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[Y] Grade A: Excellent	[Y] Grade A: Priority publishing	Google Search:	[] Accept
[] Grade B: Very good	[] Grade B: Minor language polishing	[] The same title	[] High priority for publication
[] Grade C: Good	[] Grade C: A great deal of language polishing	[] Duplicate publication	[] Rejection
[] Grade D: Fair	[] Grade D: Rejected	[Y] No	[Y] Minor revision
[] Grade E: Poor		BPG Search:	[] Major revision
		[] The same title	
		[] Duplicate publication	
		[] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

Changhoon et al describe in a “current status and future...in gastric cancer”. This is a review article which was well written and I agree with majority of it, but I would still clarify a couple of doubts. 1. Authors have to explain clearly “challenges in companion diagnosis” section using concrete proposal. (example: new biomarker, another therapeutic targets) 2. Please mention about VEGF, ramucirumab (Fuchs et al. Lancet 2014, Jan 4;383 (9911):31-9).